Regen Biopharma files provisional patent for stem cell endothelial therapy to speed hematopoietic recovery

Regen BioPharma Inc

Filed a provisional patent application with the USPTO on February 7, 2024.
Covers compositions, protocols, and treatment means for accelerating hematopoietic reconstitution.
Targets recovery after insult or chronic pathology using stem cell-derived endothelial progenitor or endothelial cells.
Application protects a potential regenerative medicine therapy for bone marrow or blood cell restoration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.